Pacira BioSciences (PCRX) EBT Margin (2010 - 2026)

Pacira BioSciences' EBT Margin history runs 17 years deep, the most recent figure standing at 2.82% for Q1 2026.

• In Q1 2026, EBT Margin fell 234.0% year-over-year to 2.82%; the TTM figure through Mar 2026 stood at 1.79% (up 1147.0% YoY), while the FY2025 annual figure was 2.32%, up 1133.0% from the prior year.
• EBT Margin was 2.82% for Q1 2026 at Pacira BioSciences, up from 0.29% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 22.34% in Q2 2023 to a low of 82.37% in Q3 2024.
• Historically, EBT Margin has averaged 1.74% across 5 years, with a median of 5.15% in 2025.
• The sharpest annual moves came in 2024 and 2025: EBT Margin slumped 9250 bps in 2024, then surged 8768 bps in 2025.
• A 5-year view of EBT Margin shows it stood at 3.77% in 2022, then surged by 394 bps to 18.6% in 2023, then decreased by 27 bps to 13.63% in 2024, then plunged by 98 bps to 0.29% in 2025, then jumped by 872 bps to 2.82% in 2026.
• The last three EBT Margin figures came in at 2.82% (Q1 2026), 0.29% (Q4 2025), and 5.31% (Q3 2025), per Business Quant data.